In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.
Kivu Bioscience Inc. has announced receipt of Human Research Ethics Committee approval and clinical trial notification clearance in Australia to initiate a first-in-human trial of KIVU-305, its CEACAM5-targeted antibody-drug conjugate.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising antibodies targeting cadherin-3 (CDH3; CDHP; P-cadherin) covalently linked to cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer.
